Lawrence E. Brieaddy

703 total citations
27 papers, 616 citations indexed

About

Lawrence E. Brieaddy is a scholar working on Molecular Biology, Organic Chemistry and Cellular and Molecular Neuroscience. According to data from OpenAlex, Lawrence E. Brieaddy has authored 27 papers receiving a total of 616 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 10 papers in Organic Chemistry and 9 papers in Cellular and Molecular Neuroscience. Recurrent topics in Lawrence E. Brieaddy's work include Nicotinic Acetylcholine Receptors Study (10 papers), Receptor Mechanisms and Signaling (9 papers) and Pharmacological Receptor Mechanisms and Effects (7 papers). Lawrence E. Brieaddy is often cited by papers focused on Nicotinic Acetylcholine Receptors Study (10 papers), Receptor Mechanisms and Signaling (9 papers) and Pharmacological Receptor Mechanisms and Effects (7 papers). Lawrence E. Brieaddy collaborates with scholars based in United States and United Kingdom. Lawrence E. Brieaddy's co-authors include Hernán A. Navarro, F. Ivy Carroll, Billy R. Martin, M. Imad Damaj, S. Wayne Mascarella, Philip Abraham, Michael C. Lewis, F. Ivy Carroll, Jeffrey R. Lee and Scott P. Runyon and has published in prestigious journals such as Journal of Medicinal Chemistry, Journal of Lipid Research and The Journal of Organic Chemistry.

In The Last Decade

Lawrence E. Brieaddy

27 papers receiving 604 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lawrence E. Brieaddy United States	17	351	210	121	99	78	27	616
Tatsuki Koike Japan	14	197 0.6×	229 1.1×	100 0.8×	115 1.2×	37 0.5×	41	642
Matthias Nettekoven Switzerland	17	250 0.7×	309 1.5×	93 0.8×	85 0.9×	10 0.1×	35	663
Ramalakshmi Y. Chandrasekaran United States	10	264 0.8×	208 1.0×	109 0.9×	69 0.7×	70 0.9×	11	612
Paul S. Humphries United States	11	152 0.4×	172 0.8×	36 0.3×	14 0.1×	44 0.6×	21	369
Kevin J. Merchant United States	18	599 1.7×	509 2.4×	454 3.8×	48 0.5×	54 0.7×	30	1.3k
Michael S. Placzek United States	16	322 0.9×	309 1.5×	101 0.8×	67 0.7×	65 0.8×	26	758
Michael W. Miller United States	13	277 0.8×	390 1.9×	59 0.5×	56 0.6×	13 0.2×	25	691
Hiroki Fujieda Japan	14	231 0.7×	338 1.6×	103 0.9×	11 0.1×	19 0.2×	22	671
Cristina Bellucci Italy	14	308 0.9×	209 1.0×	110 0.9×	59 0.6×	50 0.6×	41	516
William J. Houlihan United States	20	413 1.2×	561 2.7×	247 2.0×	80 0.8×	65 0.8×	73	1.1k

Countries citing papers authored by Lawrence E. Brieaddy

Since Specialization

Citations

This map shows the geographic impact of Lawrence E. Brieaddy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence E. Brieaddy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence E. Brieaddy more than expected).

Fields of papers citing papers by Lawrence E. Brieaddy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence E. Brieaddy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence E. Brieaddy. The network helps show where Lawrence E. Brieaddy may publish in the future.

Co-authorship network of co-authors of Lawrence E. Brieaddy

This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence E. Brieaddy. A scholar is included among the top collaborators of Lawrence E. Brieaddy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence E. Brieaddy. Lawrence E. Brieaddy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kormos, Chad M., Rangan Maitra, Scott P. Runyon, et al.. (2014). Design, Synthesis, and Biological Evaluation of (3R)-1,2,3,4-Tetrahydro-7-hydroxy-N-[(1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-isoquinolinecarboxamide (JDTic) Analogues: In Vitro Pharmacology and ADME Profile. Journal of Medicinal Chemistry. 57(17). 7367–7381. 21 indexed citations

Kormos, Chad M., Scott P. Runyon, James B. Thomas, et al.. (2014). Effect of the 3- and 4-Methyl Groups on the Opioid Receptor Properties of N-Substituted trans-3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines. Journal of Medicinal Chemistry. 57(7). 3140–3147. 5 indexed citations

Kormos, Chad M., Chunyang Jin, Scott P. Runyon, et al.. (2013). Discovery ofN-{4-[(3-Hydroxyphenyl)-3-methylpiperazin-1-yl]methyl-2-methylpropyl}-4-phenoxybenzamide Analogues as Selective Kappa Opioid Receptor Antagonists. Journal of Medicinal Chemistry. 56(11). 4551–4567. 13 indexed citations

Lewin, Anita H., et al.. (2012). Hydrolytic instability of the important orexin 1 receptor antagonist SB-334867: Possible confounding effects on in vivo and in vitro studies. Bioorganic & Medicinal Chemistry Letters. 22(21). 6661–6664. 47 indexed citations

Runyon, Scott P., Lawrence E. Brieaddy, S. Wayne Mascarella, et al.. (2010). Analogues of (3R)-7-Hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). Synthesis and in Vitro and in Vivo Opioid Receptor Antagonist Activity. Journal of Medicinal Chemistry. 53(14). 5290–5301. 24 indexed citations

Brieaddy, Lawrence E., et al.. (2008). Improved Synthesis of the ORL Antagonist 1-[(3R,4R)-1-Cyclooctylmethyl-3-ethoxycarbonyl-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397). Synthetic Communications. 38(12). 1926–1930. 1 indexed citations

Carroll, F. Ivy, Wei Ma, Jeffrey R. Lee, et al.. (2007). Synthesis, nicotinic acetylcholine receptor binding, and pharmacological properties of 3′-(substituted phenyl)deschloroepibatidine analogs. Bioorganic & Medicinal Chemistry. 16(2). 746–754. 15 indexed citations

Blough, Bruce E., Lawrence E. Brieaddy, Xiaodong Huang, et al.. (2007). Synthesis, Monoamine Transporter Binding, Properties, and Functional Monoamine Uptake Activity of 3β-[4-Methylphenyl and 4-Chlorophenyl]-2β-[5-(Substituted phenyl)thiazol-2-yl]tropanes. Journal of Medicinal Chemistry. 50(15). 3686–3695. 8 indexed citations

Carroll, F. Ivy, Wei Ma, Jeffrey R. Lee, et al.. (2005). Synthesis, Nicotinic Acetylcholine Receptor Binding, and Antinociceptive Properties of 3‘-Substituted Deschloroepibatidine Analogues. Novel Nicotinic Antagonists. Journal of Medicinal Chemistry. 48(4). 1221–1228. 23 indexed citations

10.

Carroll, F. Ivy, et al.. (2004). Synthesis, Nicotinic Acetylcholine Receptor Binding, and Antinociceptive Properties of 2‘-Fluoro-3‘-(substituted phenyl)deschloroepibatidine Analogues. Novel Nicotinic Antagonist. Journal of Medicinal Chemistry. 47(18). 4588–4594. 36 indexed citations

11.

Carroll, F. Ivy, Jeffrey R. Lee, Hernán A. Navarro, et al.. (2002). Synthesis, Nicotinic Acetylcholine Receptor Binding, and Antinociceptive Properties of 2-exo-2-(2‘,3‘-Disubstituted 5‘-pyridinyl)-7-azabicyclo[2.2.1]heptanes: Epibatidine Analogues. Journal of Medicinal Chemistry. 45(21). 4755–4761. 41 indexed citations

12.

Carroll, F. Ivy, Feng‐Xia Liang, Hernán A. Navarro, et al.. (2001). Synthesis, Nicotinic Acetylcholine Receptor Binding, and Antinociceptive Properties of 2-exo-2-(2‘-Substituted 5‘-pyridinyl)-7-azabicyclo[2.2.1]heptanes. Epibatidine Analogues. Journal of Medicinal Chemistry. 44(13). 2229–2237. 66 indexed citations

13.

Brieaddy, Lawrence E., S. Wayne Mascarella, Hernán A. Navarro, et al.. (2001). Synthesis of bridged analogs of epibatidine. 3-Chloro-5,7,8,9,9a,10-hexahydro-7,10-methanopyrrolo[1,2-b]-2,6-naphthyridine and 2-chloro-5,5a,6,7,8,10-hexahydro-5,8-methanopyrrolo[2,1-b]-1,7-naphthyridine. Tetrahedron Letters. 42(23). 3795–3797. 24 indexed citations

14.

Carroll, F. Ivy, Jeffrey R. Lee, Hernán A. Navarro, et al.. (2001). Synthesis, Nicotinic Acetylcholine Receptor Binding, and Antinociceptive Properties of 2-exo-2-(2‘-Substituted-3‘-phenyl-5‘-pyridinyl)-7-azabicyclo[2.2.1]heptanes. Novel Nicotinic Antagonist. Journal of Medicinal Chemistry. 44(24). 4039–4041. 34 indexed citations

15.

Brieaddy, Lawrence E., Feng‐Xia Liang, Philip Abraham, Jeffrey R. Lee, & F. Ivy Carroll. (1998). New synthesis of 7-(tert-butoxycarbonyl)-7-azabicyclo[2.2.1]hept-2-ene. A key intermediate in the synthesis of epibatidine and analogs. Tetrahedron Letters. 39(30). 5321–5322. 18 indexed citations

16.

Thomas, James B., Xiaoling Zheng, Lawrence E. Brieaddy, et al.. (1998). Synthesis of 9β-methyl-2-alkyl-7-oxo-5-arylmorphans. Tetrahedron Letters. 39(39). 7001–7004. 5 indexed citations

17.

Ferris, R M, Lawrence E. Brieaddy, Nariman B. Mehta, et al.. (1995). Pharmacological Properties of 403U76, a New Chemical Class of 5-Hydroxytryptamine- and Noradrenaline-reuptake Inhibitor. Journal of Pharmacy and Pharmacology. 47(9). 775–781. 33 indexed citations

18.

Winegar, Deborah A., et al.. (1995). Inhibition of ileal sodium-dependent bile acid transport by 2164U90.. Journal of Lipid Research. 36(5). 1106–1115. 34 indexed citations

19.

Brieaddy, Lawrence E., et al.. (1995). The synthesis of cis‐6,12‐Diaryl‐6H,12H‐dibenzo[b,f][1,5]dithiocin‐6,12‐imine and cis‐6,12‐Diphenyl‐6,12‐epoxy‐6H,12H‐dibenzo[b,f][1,5]dithiocin. Journal of Heterocyclic Chemistry. 32(6). 1683–1686. 3 indexed citations

20.

Brieaddy, Lawrence E., et al.. (1981). Synthesis and conformational properties of N,N-dialkyl-6,7-dihydro-5H-dibenzo[b,g][1,5]thiazocinium salts. The Journal of Organic Chemistry. 46(8). 1630–1634. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact